From NETTER to PETTER: PSMA-targeted radioligand therapy

M Eiber, K Herrmann - Journal of nuclear medicine, 2017 - Soc Nuclear Med
In this month's issue of The Journal of Nuclear Medicine, Rahbar et al. present exciting
retrospective German multicenter data (12 centers) on the performance of prostate-specific …

[PDF][PDF] Nuclear medicine beyond VISION

WP Fendler, K Herrmann, M Eiber - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
In March 2021, Novartis announced a positive result for both primary endpoints of the
randomized phase III VISION study on 177Lu-PSMA-617 radioligand therapy (RLT). 177Lu …

[PDF][PDF] To scan or not to scan: an unnecessary dilemma for PSMA radioligand therapy

S Srinivas, A Iagaru - Journal of Nuclear Medicine, 2021 - Soc Nuclear Med
The recently presented and published results of the VISION phase III study of 177Lu-
PSMA617 for metastatic castrationresistant prostate cancer (1) are indeed one of the …

Current status of PSMA-targeted radioligand therapy in the era of radiopharmaceutical therapy acquiring marketing authorization

SW Oh, M Suh, GJ Cheon - Nuclear Medicine and Molecular Imaging, 2022 - Springer
Prostate-specific membrane antigen (PSMA) is highly expressed in PCa, which gradually
increases in high-grade tumors, metastatic tumors, and tumors nonresponsive to androgen …

177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?

K Rahbar, H Ahmadzadehfar… - European Journal of …, 2018 - Springer
Dear Editor, Diagnostic and therapeutic management of metastasized prostate cancer is of
major interest, since prostate cancer is one of the most common cancers in men. During the …

213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer

M Sathekge, O Knoesen, M Meckel… - European Journal of …, 2017 - Springer
Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) with 177Lu-PSMA
holds great promise as a safe treatment option in patients with metastasized castration …

New horizons in radioligand therapy: 161Tb-PSMA-617 in advanced mCRPC

F Rosar, S Maus, A Schaefer-Schuler… - Clinical Nuclear …, 2023 - journals.lww.com
An 85-year-old man with advanced metastatic castration-resistant prostate cancer and
progression after 8 cycles of 177 Lu–prostate-specific membrane antigen (PSMA)–617 …

Exceptional 4-year response to 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer

A Gafita, H Wang, R Tauber, C D'Alessandria… - European Journal of …, 2019 - Springer
177Lu-Prostate-specific membrane antigen (177Lu-PSMA) radioligand therapy (RLT) has
demonstrated encouraging efficacy in patients with metastatic castration-resistant prostate …

[HTML][HTML] Value proposition of PSMA-targeted α–particle radioligand therapy in metastatic prostate cancer

H Jadvar - European journal of nuclear medicine and molecular …, 2019 - Springer
Theranostics is currently experiencing a renaissance since the early days of radioiodine use
in thyroid diseases. While there have been prior clinical platforms for theranostics (eg …

Salivary gland toxicity of PSMA radioligand therapy: relevance and preventive strategies

T Langbein, G Chaussé, RP Baum - Journal of Nuclear Medicine, 2018 - Soc Nuclear Med
Since the first clinical use of 131I-labeled prostate-specific membrane antigen (PSMA)(1),
xerostomia has been identified as a relevant side effect of PSMA radioligand therapies …